{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T11:14:55Z","timestamp":1788434095749,"version":"build-2803163510"},"reference-count":48,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T00:00:00Z","timestamp":1776384000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi US","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacionline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Allergy and Clinical Immunology"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.jaci.2026.01.033","type":"journal-article","created":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T23:33:57Z","timestamp":1776900837000},"page":"542-554","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Dupilumab normalizes the eosinophilic esophagitis disease transcriptome"],"prefix":"10.1016","volume":"158","author":[{"given":"Wei Keat","family":"Lim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew F.","family":"Wipperman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc E.","family":"Rothenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret H.","family":"Collins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara C.","family":"Hamon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirna","family":"Chehade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan M.","family":"Spergel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaitlyn M.","family":"Gayvert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J.","family":"Ehmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie E.","family":"Horowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annamaria B.","family":"Farrell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evan S.","family":"Dellon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Maloney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allen","family":"Radin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margee","family":"Louisias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelley","family":"Wolfe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bolanle","family":"Akinlade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dharani K.","family":"Ajithdoss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Herman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George D.","family":"Yancopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1236-5245","authenticated-orcid":false,"given":"Jennifer D.","family":"Hamilton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaci.2026.01.033_bib1","doi-asserted-by":"crossref","first-page":"128","DOI":"10.3389\/fmed.2017.00128","article-title":"Tissue remodeling in chronic eosinophilic esophageal inflammation: parallels in asthma and therapeutic perspectives","volume":"4","author":"Nhu","year":"2017","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.jaci.2026.01.033_bib2","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1053\/j.gastro.2017.06.065","article-title":"Pathophysiology of eosinophilic esophagitis","volume":"154","author":"O\u2019Shea","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jaci.2026.01.033_bib3","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1136\/gutjnl-2023-330337","article-title":"Mepolizumab for treatment of adolescents and adults with eosinophilic oesophagitis: a multicentre, randomised, double-blind, placebo-controlled clinical trial","volume":"72","author":"Dellon","year":"2023","journal-title":"Gut"},{"key":"10.1016\/j.jaci.2026.01.033_bib4","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1056\/NEJMoa2313318","article-title":"Eosinophil depletion with benralizumab for eosinophilic esophagitis","volume":"390","author":"Rothenberg","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2026.01.033_bib5","series-title":"Update on the messina phase III trial for fasenra in eosinophilic esophagitis","year":"2022"},{"key":"10.1016\/j.jaci.2026.01.033_bib6","doi-asserted-by":"crossref","first-page":"E316","DOI":"10.14309\/01.ajg.0000858424.48968.ad","article-title":"Results from KRYPTOS, a phase 2\/3 study of lirentelimab (AK002) in adults and adolescents with EoE","volume":"117","author":"Dellon","year":"2022","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jaci.2026.01.033_bib7","doi-asserted-by":"crossref","first-page":"224","DOI":"10.14309\/ajg.0000000000000474","article-title":"Mast cell infiltration is associated with persistent symptoms and endoscopic abnormalities despite resolution of eosinophilia in pediatric eosinophilic esophagitis","volume":"115","author":"Bolton","year":"2020","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jaci.2026.01.033_bib8","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1007\/s10620-018-5298-7","article-title":"Elevated tryptase in EoE is an independent phenomenon associated with extra-esophageal symptoms","volume":"64","author":"Kutty","year":"2019","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.jaci.2026.01.033_bib9","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1111\/his.13653","article-title":"Eosinophilic oesophagitis: relevance of mast cell infiltration","volume":"73","author":"Strasser","year":"2018","journal-title":"Histopathology"},{"key":"10.1016\/j.jaci.2026.01.033_bib10","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1111\/all.15260","article-title":"Mast cell-pain connection in eosinophilic esophagitis","volume":"77","author":"Zhang","year":"2022","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2026.01.033_bib11","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1108895","article-title":"Assessment of local and systemic signature of eosinophilic esophagitis (EoE) in children through multi-omics approaches","volume":"14","author":"Adel-Patient","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaci.2026.01.033_bib12","doi-asserted-by":"crossref","first-page":"331","DOI":"10.2350\/13-03-1306-OA.1","article-title":"Immunoreactivity of p53 and Ki-67 for dysplastic changes in children with eosinophilic esophagitis","volume":"16","author":"Denning","year":"2013","journal-title":"Pediatr Dev Pathol"},{"key":"10.1016\/j.jaci.2026.01.033_bib13","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.159093","article-title":"Single-cell RNA-Seq of human esophageal epithelium in homeostasis and allergic inflammation","volume":"7","author":"Rochman","year":"2022","journal-title":"JCI Insight"},{"key":"10.1016\/j.jaci.2026.01.033_bib14","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1016\/j.jaci.2022.02.025","article-title":"Single-cell RNA sequencing of mast cells in eosinophilic esophagitis reveals heterogeneity, local proliferation, and activation that persists in remission","volume":"149","author":"Ben-Baruch Morgenstern","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2026.01.033_bib15","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/gene.2014.27","article-title":"Analysis and expansion of the eosinophilic esophagitis transcriptome by RNA sequencing","volume":"15","author":"Sherrill","year":"2014","journal-title":"Genes Immun"},{"key":"10.1016\/j.jaci.2026.01.033_bib16","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1053\/j.gastro.2013.08.046","article-title":"Molecular diagnosis of eosinophilic esophagitis by gene expression profiling","volume":"145","author":"Wen","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jaci.2026.01.033_bib17","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaz7773","article-title":"Functional role of kallikrein 5 and proteinase-activated receptor 2 in eosinophilic esophagitis","volume":"12","author":"Azouz","year":"2020","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jaci.2026.01.033_bib18","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aap9736","article-title":"The antiprotease SPINK7 serves as an inhibitory checkpoint for esophageal epithelial inflammatory responses","volume":"10","author":"Azouz","year":"2018","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jaci.2026.01.033_bib19","doi-asserted-by":"crossref","first-page":"888","DOI":"10.3389\/fimmu.2018.00888","article-title":"Tuning the cytokine responses: an update on interleukin (IL)-4 and IL-13 receptor complexes","volume":"9","author":"Junttila","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaci.2026.01.033_bib20","doi-asserted-by":"crossref","first-page":"71","DOI":"10.12703\/r\/10-71","article-title":"Recent advances in understanding the role of IL-4 signaling","volume":"10","author":"Keegan","year":"2021","journal-title":"Fac Rev"},{"key":"10.1016\/j.jaci.2026.01.033_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.expneurol.2021.113909","article-title":"IL-4 expressing cells are recruited to nerve after injury and promote regeneration","volume":"347","author":"Pan","year":"2022","journal-title":"Exp Neurol"},{"key":"10.1016\/j.jaci.2026.01.033_bib22","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1111\/exd.14749","article-title":"Keratinocytes activated by IL-4\/IL-13 express IL-2R\u03b3 with consequences on epidermal barrier function","volume":"32","author":"Progneaux","year":"2023","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.jaci.2026.01.033_bib23","doi-asserted-by":"crossref","first-page":"5147","DOI":"10.1073\/pnas.1323896111","article-title":"Precise and in situ genetic humanization of 6 Mb of mouse immunoglobulin genes","volume":"111","author":"Macdonald","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jaci.2026.01.033_bib24","doi-asserted-by":"crossref","first-page":"5153","DOI":"10.1073\/pnas.1324022111","article-title":"Mice with megabase humanization of their immunoglobulin genes generate antibodies as efficiently as normal mice","volume":"111","author":"Murphy","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jaci.2026.01.033_bib25","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1080\/1744666X.2017.1298443","article-title":"Commonality of the IL-4\/IL-13 pathway in atopic diseases","volume":"13","author":"Gandhi","year":"2017","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.jaci.2026.01.033_bib26","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1111\/all.14151","article-title":"Dual blockade of IL-4 and IL-13 with dupilumab, an IL-4R\u03b1 antibody, is required to broadly inhibit type 2 inflammation","volume":"75","author":"Le Floch","year":"2020","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2026.01.033_bib27","series-title":"DUPIXENT (dupilumab). Summary of product characteristics","year":"2022"},{"key":"10.1016\/j.jaci.2026.01.033_bib28","unstructured":"DUPIXENT (dupilumab). Highlights of prescribing information. US Food and Drug Administration, Available at: https:\/\/www.regeneron.com\/downloads\/dupixent_fpi.pdf. Accessed April 10, 2025; revised September 2024."},{"key":"10.1016\/j.jaci.2026.01.033_bib29","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1056\/NEJMoa2312282","article-title":"Dupilumab for eosinophilic esophagitis in patients 1 to 11 years of age","volume":"390","author":"Chehade","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2026.01.033_bib30","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1056\/NEJMoa2205982","article-title":"Dupilumab in adults and adolescents with eosinophilic esophagitis","volume":"387","author":"Dellon","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2026.01.033_bib31","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1053\/j.gastro.2019.09.042","article-title":"Efficacy of dupilumab in a phase 2 randomized trial of adults with active eosinophilic esophagitis","volume":"158","author":"Hirano","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jaci.2026.01.033_bib32","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/S2468-1253(23)00204-2","article-title":"Efficacy and safety of dupilumab up to 52 weeks in adults and adolescents with eosinophilic oesophagitis (LIBERTY EoE TREET study): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial","volume":"8","author":"Rothenberg","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jaci.2026.01.033_bib34","first-page":"504","article-title":"Master regulators used as breast cancer metastasis classifier","author":"Lim","year":"2009","journal-title":"Pac Symp Biocomput"},{"key":"10.1016\/j.jaci.2026.01.033_bib35","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1172\/JCI26679","article-title":"Eotaxin-3 and a uniquely conserved gene-expression profile in eosinophilic esophagitis","volume":"116","author":"Blanchard","year":"2006","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jaci.2026.01.033_bib36","doi-asserted-by":"crossref","unstructured":"Rothenberg ME, Lim WK, Wipperman MF, Chehade M, Dellon ES, Hundal NV, et al. Dupilumab normalized the expression of genes dysregulated in eosinophilic esophagitis (EoE) in esophageal biopsies from a clinical trial of children aged 1\u201311 years. Oral presentation at: American Academy of Asthma, Allergy & Immunology; February 23-26, 2024, Washington, DC.","DOI":"10.1016\/j.jaci.2023.11.485"},{"key":"10.1016\/j.jaci.2026.01.033_bib50","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.jaci.2010.04.009","article-title":"Involvement of mast cells in eosinophilic esophagitis","volume":"126","author":"Abonia","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2026.01.033_bib51","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0067560","article-title":"Identification of genes expressed by human airway eosinophils after an in vivo allergen challenge","volume":"8","author":"Esnault","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jaci.2026.01.033_bib37","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1177\/10935266211041086","article-title":"Acquired esophageal strictures in children: morphometric and immunohistochemical analyses","volume":"25","author":"Collins","year":"2022","journal-title":"Pediatr Dev Pathol"},{"key":"10.1016\/j.jaci.2026.01.033_bib38","doi-asserted-by":"crossref","first-page":"G1175","DOI":"10.1152\/ajpgi.00313.2012","article-title":"Tissue remodeling in eosinophilic esophagitis","volume":"303","author":"Cheng","year":"2012","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1016\/j.jaci.2026.01.033_bib39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1053\/j.gastro.2023.09.004","article-title":"Ascending to new heights for novel therapeutics for eosinophilic esophagitis","volume":"166","author":"Hirano","year":"2024","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jaci.2026.01.033_bib40","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1159\/000357012","article-title":"Histopathology of eosinophilic esophagitis","volume":"32","author":"Collins","year":"2014","journal-title":"Dig Dis"},{"key":"10.1016\/j.jaci.2026.01.033_bib41","doi-asserted-by":"crossref","first-page":"66","DOI":"10.4292\/wjgpt.v7.i1.66","article-title":"Eosinophilic esophagitis: new insights in pathogenesis and therapy","volume":"7","author":"Guarino","year":"2016","journal-title":"World J Gastrointest Pharmacol Ther"},{"key":"10.1016\/j.jaci.2026.01.033_bib42","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1159\/000357004","article-title":"Remodeling and fibrosis in chronic eosinophil inflammation","volume":"32","author":"Aceves","year":"2014","journal-title":"Dig Dis"},{"key":"10.1016\/j.jaci.2026.01.033_bib43","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/nrd4624","article-title":"Targeting key proximal drivers of type 2 inflammation in disease","volume":"15","author":"Gandhi","year":"2016","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.jaci.2026.01.033_bib44","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.jaci.2018.08.022","article-title":"Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis","volume":"143","author":"Guttman-Yassky","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2026.01.033_bib45","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/j.jaci.2014.10.013","article-title":"Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis","volume":"134","author":"Hamilton","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2026.01.033_bib48","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.gtc.2014.02.007","article-title":"Histopathologic features of eosinophilic esophagitis and eosinophilic gastrointestinal diseases","volume":"43","author":"Collins","year":"2014","journal-title":"Gastroenterol Clin North Am"},{"key":"10.1016\/j.jaci.2026.01.033_bib49","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s00535-019-01624-3","article-title":"Clinical relevance of esophageal subepithelial activity in eosinophilic esophagitis","volume":"55","author":"Hirano","year":"2020","journal-title":"J Gastroenterol"}],"container-title":["Journal of Allergy and Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674926002630?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674926002630?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T10:19:31Z","timestamp":1788430771000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091674926002630"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":48,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S0091674926002630"],"URL":"https:\/\/doi.org\/10.1016\/j.jaci.2026.01.033","relation":{},"ISSN":["0091-6749"],"issn-type":[{"value":"0091-6749","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dupilumab normalizes the eosinophilic esophagitis disease transcriptome","name":"articletitle","label":"Article Title"},{"value":"Journal of Allergy and Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaci.2026.01.033","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology.","name":"copyright","label":"Copyright"}]}}